Know Cancer

or
forgot password

STUDY OF USE OF PEMETREXED IN PATIENTS WITH NON-SMALL LUNG CANCER METASTATIC IN ANDALUSIAN PUBLIC HEALTH SYSTEM


N/A
N/A
N/A
Open (Enrolling)
Both
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

STUDY OF USE OF PEMETREXED IN PATIENTS WITH NON-SMALL LUNG CANCER METASTATIC IN ANDALUSIAN PUBLIC HEALTH SYSTEM


Inclusion Criteria:



- Patients over 18 years

- Confirmed diagnosis of metastatic NSCLC

- Pemetrexed Starts 1st line (either induction or maintenance) in any of the following
periods:

- January 1, 2010 to March 31, 2010

- October 1, 2011 to December 31, 2011

Exclusion Criteria:

- Patients receiving pemetrexed within a clinical trial protocol because it is an
experimental environment that does not reflect clinical practice.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Determine utilization profile (line treatment and scheme used) of pemetrexed in patients with non-small cell lung cancer metastatic (CPNMm) in Andalusia.

Outcome Time Frame:

12 months

Safety Issue:

No

Principal Investigator

Javier Bautista Paloma

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hospital Universitario Virgen del Rocío

Authority:

Spain: Ethics Committee

Study ID:

FPS-PEM-2013-06

NCT ID:

NCT01877902

Start Date:

October 2011

Completion Date:

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location